Neovasc Inc.
13700 Mayfield Place
Suite 2135
Richmond
British Columbia
V6V 2E4
Canada
Tel: 604-270-4344
Fax: 604-270-4384
Website: http://www.neovasc.com/
Email: info@neovasc.com
379 articles about Neovasc Inc.
-
Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.
-
Neovasc Reducer Featured in Live Case at Berlin Symposium
1/18/2018
The successful live case was performed by Dr. Spyrantis and Professor Banai in the Sana-Klinikum Lichtenberg.
-
Neovasc Reports Tiara's Clinical Case Load Accelerating
1/8/2018
Neovasc today provided an update on its clinical program for the Tiara valve.
-
Neovasc Inc. Receives NASDAQ Notification Regarding Minimum Bid Requirements
1/3/2018
Neovasc announced today that it has received written notification Nasdaq notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.
-
Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants
11/17/2017
The Company intends to use the net proceeds from the Offering and Concurrent Private Placement to fully fund the approximately US$42M balance of the damages and interest awards granted in the litigation with CardiAQ.
-
Neovasc Announces Results for the Third Quarter of 2017
11/15/2017
Revenues decreased 55% to $1,374,893 for the three months ended September 30, 2017, compared to revenues of $3,034,000 for the same period in 2016.
-
Neovasc Inc. to Host Third Quarter 2017 Conference Call
11/13/2017
The Company will subsequently hold a conference call that same day at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, CEO, and Mr. Chris Clark, CFO.
-
Neovasc Announces $65M Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants
11/10/2017
The price of $1.46 per Unit represents the market price of Neovasc's common shares as of the date of this news release.
-
Neovasc Receives FDA Approval to Initiate Pivotal Reducer Trial
11/6/2017
The trial's purpose will be to demonstrate the safety and effectiveness of the Company's novel Reducer system for treatment of patients with refractory angina.
-
Neovasc Provides Litigation Update
11/6/2017
In summary, the appeals process is now exhausted.
-
The trial's purpose will be to demonstrate the safety and effectiveness of the Company's novel Reducer system for treatment of patients with refractory angina.
-
Neovasc Provides Tiara Clinical Update
9/12/2017
-
Neovasc's Reducer System Reviewed In European Heart Journal
9/5/2017
-
Neovasc Announces Results For The Second Quarter Of 2017
8/11/2017
-
Neovasc To Host Second Quarter 2017 Conference Call
8/3/2017
-
Neovasc Announces Positive IDSMB Review For Phase Iib Clinical Trial Of Ifnalpha Kinoid In Lupus
7/11/2017
-
Neovasc Announces German Court Ruling
6/16/2017
-
Neovasc Tiara Featured In TVT 2017 Presentation
6/15/2017
-
Neovasc Reports Results Of Annual General Meeting Of Shareholders
6/14/2017
-
Neovasc Announces Results For The First Quarter Of 2017
5/11/2017